Don't show this message again
42 U.S. Code § 2160d. Further restrictions on exports
(a) In generalExcept as provided in subsection (b), the Commission may issue a license for the export of highly enriched uranium to be used as a fuel or target in a nuclear research or test reactor only if, in addition to any other requirement of this chapter, the Commission determines that—
(1)
there is no alternative nuclear reactor fuel or target enriched in the isotope 235 to a lesser percent than the proposed export, that can be used in that reactor;
(2)
the proposed recipient of that uranium has provided assurances that, whenever an alternative nuclear reactor fuel or target can be used in that reactor, it will use that alternative in lieu of highly enriched uranium; and
(3)
the United States Government is actively developing an alternative nuclear reactor fuel or target that can be used in that reactor.
(b) Medical isotope production
(1) DefinitionsIn this subsection:
(A) Highly enriched uranium
The term “highly enriched uranium” means uranium enriched to include concentration of U–235 above 20 percent.
(B) Medical isotope
The term “medical isotope” includes Molybdenum 99, Iodine 131, Xenon 133, and other radioactive materials used to produce a radiopharmaceutical for diagnostic, therapeutic procedures or for research and development.
(C) RadiopharmaceuticalThe term “radiopharmaceutical” means a radioactive isotope that—
(i)
contains byproduct material combined with chemical or biological material; and
(ii)
is designed to accumulate temporarily in a part of the body for therapeutic purposes or for enabling the production of a useful image for use in a diagnosis of a medical condition.
(D) Recipient country
The term “recipient country” means Canada, Belgium, France, Germany, and the Netherlands.